Stock comparison
Moderna, Inc. is 19.9x more valuable than Inhibrx, Inc. by market capitalization ($30.38 B vs $1.53 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
MRNA is larger
Moderna, Inc. is 19.9x more valuable than Inhibrx, Inc. by market capitalization ($30.38 B vs $1.53 B).
Market value leader
MRNA
Moderna, Inc. is 19.9x more valuable than Inhibrx, Inc. by market capitalization ($30.38 B vs $1.53 B).
Revenue leader
MRNA
INBX: $1.80M vs MRNA: $1.94B.
Profit leader
INBX
INBX: -$241.36M vs MRNA: -$2.82B.
Margin leader
MRNA
INBX: -13408.9% vs MRNA: -145.2% net margin.
| Metric | INBX | MRNA |
|---|---|---|
| Market cap | $1.53 B | $30.38 B |
| US-listed rank | #2346 | #461 |
| Revenue (latest FY) | $1.80M | $1.94B |
| Net income (latest FY) | -$241.36M | -$2.82B |
| Net margin | -13408.9% | -145.2% |
| P/E (trailing FY) | - | - |
| SEC filings | 261 | 1,447 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Moderna, Inc. is 19.9x more valuable than Inhibrx, Inc. by market capitalization ($30.38 B vs $1.53 B).
Full pages: Inhibrx, Inc. and Moderna, Inc., or browse the full rankings.